Payment overview · 2025
General Payments
$2,242.18
119 reported records · 36 companies
Healthcare provider profile · identity verified
David L Ewing, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SAINT JOSEPH, MO · NPI 1639283369
Verified facts
What the public records show
CMS Open Payments records show David L Ewing, MD received $2,242.18 in general payments during 2025 across 119 reported records.
ABBVIE INC. accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Fycompa, Gamunex-C, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ubrelvy by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Fycompa by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gamunex-C by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $325.60 | 14.5% | 34 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $179.90 | 8.0% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$154.86 | 6.9% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $144.99 | 6.5% | 8 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $135.55 | 6.0% | 9 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $99.66 | 4.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $97.83 | 4.4% | 4 | 2025 |
| PIRAMAL CRITICAL CARE | Unresolved — no canonical attribution shown | $90.48 | 4.0% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $76.82 | 3.4% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.22 | 3.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $70.42 | 3.1% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $68.11 | 3.0% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.84 | 2.8% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $59.09 | 2.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.36 | 1.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.56 | 1.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $41.23 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.60 | 1.7% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $35.95 | 1.6% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $33.40 | 1.5% | 2 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $33.09 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.81 | 1.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $30.64 | 1.4% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $29.51 | 1.3% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $28.94 | 1.3% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $24.50 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.31 | 1.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$23.69 | 1.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $22.52 | 1.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $20.99 | 0.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.84 | 0.8% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.26 | 0.8% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $16.61 | 0.7% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $16.59 | 0.7% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.22 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.19 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,242.18 | 119 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $245.89 | 28 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $189.20 | 20 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $179.90 | 6 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $154.86 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $99.66 | 5 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $97.83 | 4 | 2025 |
Source payment records
|
|||||
| GABLOFEN Normalized: gablofen |
Drug | PIRAMAL CRITICAL CARE | $90.48 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $79.61 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $73.22 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $64.11 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $61.84 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $61.48 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $55.94 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $49.18 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $46.99 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $41.56 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $41.23 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $30.64 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 81 | exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 69 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
81 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 595 | 99 |
| Topiramate | Topiramate | 559 | 102 |
| Levetiracetam | Levetiracetam | 540 | 97 |
| Donepezil Hcl | Donepezil Hcl | 467 | 102 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 454 | 92 |
| Pregabalin | Pregabalin | 454 | 70 |
| Lacosamide | Lacosamide | 450 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 430 | 101 |
| Gabapentin | Gabapentin | 400 | 80 |
| Baclofen | Baclofen | 373 | 85 |
| Nortriptyline Hcl | Nortriptyline Hcl | 299 | 55 |
| Ropinirole Hcl | Ropinirole Hcl | 289 | 64 |
| Memantine Hcl | Memantine Hcl | 244 | 52 |
| Lamotrigine | Lamotrigine | 175 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 156 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 33 |
| Amantadine | Amantadine Hcl | 111 | 23 |
| Propranolol Hcl Er | Propranolol Hcl | 110 | 23 |
| Aimovig Autoinjector | Erenumab-Aooe | 108 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 106 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 91 | 32 |
| Aripiprazole | Aripiprazole | 85 | 16 |
| Carbamazepine | Carbamazepine | 85 | 13 |
| Briviact | Brivaracetam | 81 | 12 |
| Diazepam | Diazepam | 74 | 44 |
| Oxcarbazepine | Oxcarbazepine | 74 | 13 |
| Carbamazepine Er | Carbamazepine | 72 | 14 |
| Divalproex Sodium | Divalproex Sodium | 70 | 14 |
| Qulipta | Atogepant | 69 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 16 |
| Entacapone | Entacapone | 65 | 15 |
| Sertraline Hcl | Sertraline Hcl | 62 | 21 |
| Tramadol Hcl | Tramadol Hcl | 60 | suppressed |
| Primidone | Primidone | 58 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 13 |
| Phenobarbital | Phenobarbital | 50 | suppressed |
| Zonisamide | Zonisamide | 50 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 11 |
| Trazodone Hcl | Trazodone Hcl | 45 | 14 |
| Austedo | Deutetrabenazine | 41 | suppressed |
| Fycompa | Perampanel | 36 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 36 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Ubrelvy | Ubrogepant | 32 | suppressed |
| Dalfampridine Er | Dalfampridine | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Clozapine | Clozapine | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 27 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 26 | 11 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Azathioprine | Azathioprine | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | 12 |
| Ethosuximide | Ethosuximide | 20 | suppressed |
| Keppra | Levetiracetam | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Clobazam | Clobazam | 17 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 17 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Vimpat | Lacosamide | 16 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Carbidopa | Carbidopa | 14 | suppressed |
| Glatopa | Glatiramer Acetate | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,242.18 · 119 records | ABBVIE INC. | ACTHAR, AMVUTTRA, AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, EPIDIOLEX, FYCOMPA, Fintepla, GABLOFEN, Gamunex-C, Gocovri, INFINITY, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, ONGENTYS, Ocrevus Zunovo, PERCEPT PC BRAINSENSE, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, Rystiggo, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAKIX, XYWAV, ZEPOSIA, ZTLido | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error